Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 606-970-7 | CAS number: 222716-77-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- of 1996
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Details on test material:
- - Name of test material (as cited in study report): WS400506
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Sprague Dawley rats, strain: Crl:CD(SD) with appropriate range of bodyweight at study start.
- Source: Charles River (UK) Ltd.
- Age at treatment start: Ca. 70 days.
- Weight at treatment start: Males: minimum 348 g, maximum 390 g,
Females: minimum 218 g, maximum 267 g.
- Housing Inside a barriered rodent facility:
all animals pre-pairing + toxicity subgroups: In groups up to 5 by sex in solid floor polycarbonate cages.
during pairing (1 male+1 female/cage): In RB3 modified polypropylene cages with stainless steel grid-floor over absorbent paper-lined trays.
males after pairing: In groups up to 5 in solid floor polycarbonate cages.
females during gestation and lactation: Females housed individually (+litter) in solid floor polycarbonate cages.
- Bedding material (in solid floor cages): Wood based bedding, sterilised by autoclaving before use.
- Cage enrichment: Aspen chew block + plastic shelter (except during pairing or post gestation day 20).
- Diet (ad libitum): Standard rodent diet (SDS VRF1 Certified) without antibiotic, chemotherapeutic or prophylactic agent.
- Fasting (diet withheld): Main phase males and Toxicity phase females overnight before blood sampling for clinical pathology.
- Water (ad libitum): Potable drinking water from the public supply.
- Acclimation period: 5 days before treatment start, under laboratory conditions.
Routine analysis of the batch of diet used and water, chew blocks and bedding material did not provide evidence of contamination that might have prejudiced the study.
IN-LIFE DATES:
- Duration of test, males & toxicity phase females: Five weeks
Duration of test, main phase females (i.e. reproductive subgroup): From 14 days prior to pairing to day 7 of lactation.
Duration of test, offspring: From birth to day 7 of lactation.
ENVIRONMENTAL CONDITIONS
Air conditioned room kept at positve pressure without re-circulation of the filtered fresh air supplied to the room.
Controlled environment, environmental conditions were set at:
- Temperature (°C): 21 ± 2°C
- Relative Humidity (%): 40 to 70%
- Photoperiod (artificial lighting): 12 hrs day / 12 hrs night
- Rate of air exchange: At least 15 changes/h
Deviations from the target ranges for temperature and relative humidity were not evident.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- - Concentration in vehicle: The concentration of the test material in vehicle varied between dose groups thus allowing constant dosage volume in terms of mL/kg bw/day.
- Amount (dose volume by gavage): 5 mL/kg bw/day..
Actual dose volumes were calculated at about weekly or shorter intervals accounting for the latest body weight. Litter animals were not dosed.
- For concentrations of test material in vehicle at different dose levels, see Table 1 in "Any other information on materials and methods incl. tables"
- Justification for choice of vehicle:
The suitability of corn oil as a vehicle was established visually and by chemical analysis during the 7-day range-finding study:
Endpoint study record "7.5.1 Repeated dose toxicity: oral - 7d_range-finding_gavage_HLS_GAH0043".
In addition, in the present main study, concentrations of dose formulations were chemically analysed. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Chemical analysis of test material formulations by high performance liquid chromatography coupled with a mass spectrometer (HPLC-MS/MS).
- Concentrations (verified at first and last treatment week) of the test material formulations were confirmed at each dose level.
- Chemical analysis confirmed that the mean concentrations of WS400506 in prepared formulations were 89.5% to 99.5% of the corresponding
nominal concentration, thus confirming accuracy of formulation. - Duration of treatment / exposure:
- - Treatment period, males & toxicity phase females: Daily, for five consecutive weeks, in males commencing 14 days prior to pairing
- Treatment period, main phase females (i.e. reproductive subgroup): 44 to 56 days (from 14 days prior to pairing to day 6 of lactation)
- Offspring were not dosed - Frequency of treatment:
- Daily, 7 days/week (during parturition, dosing omitted as appropriate)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Toxicity phase animals: */ 5 females
Main phase animals (i.e. reproductive subgroups): 10 males / 10 females
*Explanatory note by the notifier:
Examinations assigned to the toxicity phase females to meet the requirements of a 28-day repeat dose oral toxicity study were also assigned to 5 (for some examinations to 10) main phase males per dose group. Therefore, these 5 main phase males per dose group are called also "toxicity subgroup" in the present robust study summary for clarification. After pairing with main phase females, all males were killed at the same time (Week 6). - Control animals:
- yes, concurrent vehicle
- Details on study design:
- This study was conducted to examine both repeated dose toxicity and reproductive/developmental toxicity as an OECD screening combined study
(OECD 422 test guideline). Therefore, animals initially entering the study were divided into toxicity subgroup animals (toxicity phase) and reproductive subgroup animals (main phase), whereby 5 of the 10 F0 males (used for pairing) per dose group formed the toxicity male subgroups.
Dose selection was based on the results of a 7-day preliminary oral toxicity study in the rat in which dose levels of 100, 300 or 1000 mg/kg/day did not have any overt treatment-related effects on young adult animals (females nulliparous and non-pregnant). - Positive control:
- Not included in the study.
Examinations
- Observations and examinations performed and frequency:
- Clinical observations performed and frequency:
- Clinical signs : At least twice a day (before and after administration)
- Detailed physical examination
and arena observations: Before treatment start and at least once a treatment week.
- Functional Observation Battery:* During treatment week 5 (before dosing) on all toxicity subgroup animals (5 males + 5 females/group).
- Body weight, all males: Weekly throughout the study.
Body weight, Toxicity Females: Weekly throughout the study.
Body weight, Repro. Females: Weekly for pre-pairing period; on gestation days 0, 6, 13, 20; on lactation days 1 & 7.
- Food consumption, all males: Weekly for pre-pairing period and for the period after mating.
Food cons., Toxicity Females: About weekly throughout the study.
Food cons., Repro. Females: Weekly for pre-pairing period, during gestation for days 0-6, 6-13, 13-20, during lactation for days 1-4 & 4-7.
* FOB including sensory reactivity tests (approach, touch, auditory startle reflex, tail pinching), grip strength and motor activity.
Hematological examinations (only for toxicity subgroup animals) during treatment week 5 after functional observation battery:
Red blood cell count, reticulocyte count, white blood cell count, platelet count, hemoglobin concentration, hematocrit value, differential leukocyte counts,
protrombin time, activated partial thromboplastin time, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration.
Blood (plasma) chemical examinations (only for toxicity subgroup animals) during treatment week 5 after functional observation battery:
Total protein, albumin, A/G ratio, urea, creatinine, glucose, total cholesterol, total bilirubin, bile acids, sodium, potassium, chloride,
calcium, inorganic phosphorus, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase.
This study was conducted to examine both repeated dose toxicity and reproductive/developmental toxicity as an OECD screening combined study
(OECD 422 test guideline). Therefore, some of the examinations were confined to toxicity subgroup animals, as indicated above. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, see below
WEIGHING OF ORGANS: Yes, see below
HISTOPATHOLOGY: Yes, see below
Terminal sacrifice
- all males and toxicity subgr. females: Killed in Week 6, after completion of the Treatment Week 5 investigations.
- reproductive subgr. females & offspring: Killed on Day 7 post partum.
2 control females which failed to mate or were without viable litter were killed on Day 25 after the last day of pairing.
Gross pathology:
- adult/parental animals: Full macroscopic examination with tissue collection.
- offspring: Full macroscopic examination including assessment of the presence of milk in the stomach, where possible.
(Missing or grossly autolysed or cannibalised offspring could not be examined).
Organs Weights:
- main phase and tox. subgr. adults: Adrenals, brain, epididymides, heart, kidneys, liver, lungs & bronchi, ovaries, pituitary, prostate, seminal vesicles
& coagulation gland, spleen, testes, thymus, thyroid with parathyroids, uterus with cervix & oviducts.
Histopathology:
- toxicity subgroups: The following organs were microscopically observed for the control and 1000 mg/kg bw/day groups:
Brain, eyes, Harderian glands, optic nerves, pituitary gland, thyroid with parathyroids, heart, thymus, liver, spleen,
adrenals, kidneys, testes, epididymides, ovaries, lung, trachea, esophagus, stomach, duodenum, jejunum, ileum,
caecum, rectum, colon, Peyer's patch, lymph node (axillary, mesenteric), urinary bladder, uterus (with cervix &
oviducts), vagina, spinal cord, sciatic nerve, skeletal muscle, skin with mammary glands, sternum with marrow,
seminal vesicle & coagulation gland, prostate. In addition, the jejunum, mesenteric lymph nodes and duodenum
were also examined for the 100 and 300 mg/kg bw/day toxicity subgroups and any gross lesions for all adult animals. - reproductive subgroups Gross lesions from all adult animals from all dose groups were examined by light microscopy. - Other examinations:
- Reproductive and developmental toxicity parameters (addressed in separate endpoints).
- Statistics:
- Grip strength, motor activity, bodyweight, food consumption, organ weight, gestation length, litter size, survival indices & clinical pathology data were statistically analysed by adoption of the following sequence of tests:
- Parametric analysis, if Bartlett's test for variance homogeneity was not significant at the 1% level.
F1 approximate test for monotonicity of dose-response. If this F1 test was not significant at the 1% level, Williams' test for a monotonic trend was applied.
If this F1 test was significant, suggesting that the dose-response was not monotone , the Dunnett's test was performed instead.
- Non-parametric analysis, if Bartlett's test was still significant at the 1% level following logarithmic and square-root transformations.
H1 approximate test for monotonicity of dose-response. If this H1 test was not significant at the 1% level, Shirley's test for a monotonic trend was applied.
If this H1 test was significant, suggesting that the dose-response was not monotone, the Steel's test was performed instead.
-For grip strength, motor activity, survival indices and clinical pathology data, if 75% of the data (across all groups) were the same value,
pairwise comparison of each dose group against the control by Fisher’s Exact tests.
-For organ weight data, covariance analysis using terminal bodyweight as covariate (Angervall & Carlstrom, 1963).
Sex ratio
- Analysis by generalised mixed linear model with binomial errors, a logit link function and litter as a random effect (Lipsitz et al 1991).
Each treated group was compared to control using a Wald chi-square test.
Gestation length
- Exact (or asymptotic) two-tailed Linear-by-linear test (Cytel 1995), with equally spaced scores. If the test was statistically significant (p<0.05), the highest
dose group was excluded and the test re-applied until the test was no longer statistically significant (p≥0.05).
For statistical references, see next field.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- only in males at 1000 mg/kg/day. See figures on body weight attached as background material.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- See tables on food consumption attached as background material.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- See tables on haematology and clinical chemistry attached as background material.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- See tables on haematology and clinical chemistry attached as background material.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Functional observation battery including sensory reactivity tests (approach, touch, auditory startle reflex, tail pinching), grip strength, motor activity and attention to clinical signs of neurotoxicity during animal observations.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- mesenteric lymph node, duodenum, jejunum
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS, NEUROBEHAVIOUR AND MORTALITY
One control female was found dead following an intubation error. Two other control females which failed to mate or were without viable litter were killed on Day 25 after their last day of pairing. Clinical signs attributable to treatment with the test material or effects on sensory reactivity, grip strength or motor activity were not evident.
BODY WEIGHT AND WEIGHT GAIN
Overall bodyweight gain was low in males receiving 1000 mg/kg/day, but unaffected in males at lower dose levels and females at all dose levels (see Tables 2 and 3).
FOOD CONSUMPTION
Food consumption was unaffected by treatment with the test material.
CLINICAL PATHOLOGY
Haematology parameters were unaffected by treatment with the test material. Raised cholesterol levels in both sexes at 1000 mg/kg/day on their own and with no pathological correlate were considered fortuitous and toxicologically not significant.
GROSS PATHOLOGY
Macroscopic findings attributable to treatment with the test material were not evident.
ORGAN WEIGHTS
Adjusted mean adrenal weights and mean ovary weights lower than concurrent controls in all treated groups after 5 treatment weeks were considered to be fortuitous and toxicologically not significant, as there were no histopathological correlates. Following lactation, mean ovary weight was unaffected by treatment.
HISTOPATHOLOGY: NON-NEOPLASTIC
Lymphatic ectasia in the mesenteric lymph node of males at 1000 mg/kg/day and females at 300 and 1000 mg/kg/day and cystic dilation of the central lymphatic or lacteal in the villi of the duodenum and jejunum in both sexes at 300 and 1000 mg/kg/day (see Table 4) were attributed to treatment with the test material. However, only in males at 1000 mg/kg/day these findings were considered to represent an adverse effect, because in this group they may have affected digestive function thus contributing to the low body weight gain. In all groups, the intestinal changes were not associated with any inflammatory or degenerative changes.
Plasmacytosis in the mesenteric lymph node in males of all groups treated with WS400506 and in one control female and one female of the 300 mg/kg/day group was considered to be a non specific reactive change of no toxicological importance.
OTHER RESULTS
Reproductive and developmental toxicity parameters are addressed in separate endpoints.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Lymphatic ectasia in the mesenteric lymph node and cystic dilation of the central lymphatic or lacteal in the villi of the duodenum and jejunum associated with low bodyweight gain at 1000 mg/kg/day were considered to be adverse.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: NOAEL = highest dose tested. In the absence of adverse effects on bodyweight in females, histopathology findings similar to those in males were not considered to be adverse.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 2: Bodyweight and Bodyweight Change - Group Mean Values (g) for Main and Toxicity Phase Animals – Males |
||||||||||||
Group |
1 |
2 |
3 |
4 |
||||||||
Compound |
Vehicle Control |
WS400506 |
WS400506 |
WS400506 |
||||||||
Dose (mg/kg/day) |
0 |
100 |
300 |
1000 |
||||||||
|
||||||||||||
Group/Sex |
Week |
Week |
Week |
Week |
Week |
Week |
|
Change |
Change |
Change |
||
|
0 |
1 |
2 |
3 |
4 |
5 |
|
0-2 |
2-5 |
0-5 |
||
Statistical test: |
Wi |
Wi |
Wi |
Wi |
Wi |
Wi |
|
Wi |
Wi |
Wi |
||
1/M |
Mean |
367 |
401 |
433 |
449 |
474 |
489 |
|
66 |
56 |
122 |
|
|
SD |
11.4 |
13.5 |
17.6 |
16.8 |
23.0 |
33.2 |
|
8.9 |
18.3 |
26.3 |
|
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
10 |
10 |
10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/M |
Mean |
367 |
405 |
430 |
449 |
469 |
482 |
|
63 |
51 |
115 |
|
|
SD |
10.7 |
14.1 |
19.4 |
21.6 |
23.1 |
24.1 |
|
12.6 |
10.8 |
17.5 |
|
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
10 |
10 |
10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/M |
Mean |
367 |
399 |
424 |
446 |
471 |
481 |
|
57 |
57 |
114 |
|
|
SD |
10.5 |
11.7 |
16.9 |
17.3 |
17.1 |
19.4 |
|
13.1 |
11.0 |
17.5 |
|
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
10 |
10 |
10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4/M |
Mean |
365 |
391 |
413* |
424** |
448** |
453** |
|
47** |
40* |
87** |
|
|
SD |
13.2 |
15.7 |
16.5 |
16.8 |
17.1 |
16.7 |
|
8.0 |
14.6 |
16.7 |
|
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
10 |
10 |
10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Statistical test Wi = Treated groups compared to Control using Williams’ test, * p<0.05, ** p<0.01
Table 3: Bodyweight and Bodyweight Change - Group Mean Values (g) for Main and Toxicity Phase Animals – Females |
||||||||||||
Group |
1 |
2 |
3 |
4 |
||||||||
Compound |
Vehicle Control |
WS400506 |
WS400506 |
WS400506 |
||||||||
Dose (mg/kg/day) |
0 |
100 |
300 |
1000 |
||||||||
|
||||||||||||
Group/Sex |
Week |
Week |
Week |
Week |
Week |
Week |
|
Change |
Change |
Change |
||
|
0 |
1 |
2 |
3‡ |
4‡ |
5‡ |
|
0-2 |
2-5‡ |
0-5‡ |
||
Statistical test: |
Wi |
Wi |
Wi |
Wi |
Wi |
Wi |
|
Wi |
Wi |
Wi |
||
1/F |
Mean |
240 |
244 |
254 |
277 |
289 |
283 |
|
14 |
23 |
42 |
|
|
SD |
10.5 |
10.6 |
12.7 |
11.0 |
10.1 |
10.1 |
|
10.7 |
7.0 |
6.8 |
|
|
N |
15 |
15 |
15 |
5 |
5 |
5 |
|
15 |
5 |
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/F |
Mean |
236 |
241 |
252 |
264 |
272 |
274 |
|
17 |
23 |
39 |
|
|
SD |
11.0 |
12.3 |
13.0 |
9.8 |
13.5 |
13.6 |
|
7.6 |
9.4 |
7.5 |
|
|
N |
15 |
15 |
15 |
5 |
5 |
5 |
|
15 |
5 |
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3/F |
Mean |
235 |
244 |
253 |
264 |
275 |
277 |
|
18 |
23 |
42 |
|
|
SD |
7.4 |
11.4 |
13.0 |
16.8 |
22.4 |
18.3 |
|
11.7 |
11.6 |
13.6 |
|
|
N |
15 |
15 |
15 |
5 |
5 |
5 |
|
15 |
5 |
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4/F |
Mean |
237 |
248 |
256 |
274 |
287 |
288 |
|
20 |
28 |
50 |
|
|
SD |
8.2 |
7.9 |
7.4 |
9.0 |
14.2 |
11.5 |
|
8.6 |
8.1 |
10.8 |
|
|
N |
15 |
15 |
15 |
5 |
5 |
5 |
|
15 |
5 |
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
‡ Toxicity phase animals only
Statistical test Wi = Treated groups compared to Control using Williams’ test, * p<0.05, ** p<0.01
Table 4:Summary of Treatment Related Findings for Toxicity Phase Animals Killed after 5 Treatment Weeks |
||||||||
Group/Sex |
1/M |
2/M |
3/M |
4/M |
1/F |
2/F |
3/F |
4/F |
Dose (mg/kg/day) |
0 |
100 |
300 |
1000 |
0 |
100 |
300 |
1000 |
|
|
|||||||
Mesenteric Lymph Node |
|
|||||||
Lymphatic ectasia |
|
|||||||
Minimal Slight Moderate |
0 0 0 |
0 0 0 |
0 0 0 |
1 2 2 |
0 0 0 |
0 0 0 |
1 0 0 |
1 2 1 |
Total
|
0 |
0 |
0 |
5 |
0 |
0 |
1 |
4 |
Plasmacytosis |
|
|
|
|
|
|
|
|
Minimal |
0 0 |
3 2 |
3 2 |
2 1 |
0 1 |
0 0 |
0 1 |
0 0 |
Slight |
||||||||
Total |
0 |
5 |
5 |
3 |
1 |
0 |
1 |
0 |
|
|
|
|
|
|
|
|
|
Number of tissues examined |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
|
|
|||||||
Duodenum |
|
|||||||
Cystic dilation of the central lymphatic within villi |
|
|||||||
Minimal Slight Moderate |
0 0 0 |
0 0 0 |
1 0 0 |
1 3 1 |
0 0 0 |
0 0 0 |
2 0 0 |
2 2 1 |
Total |
0 |
0 |
1 |
5 |
0 |
0 |
2 |
5 |
|
|
|
|
|
|
|
|
|
Number of tissues examined |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
|
|
|||||||
Jejunum |
|
|||||||
Cystic dilation of the central lymphatic within villi |
|
|||||||
Minimal Slight Moderate |
0 0 0 |
0 0 0 |
1 0 0 |
1 0 3 |
0 0 0 |
0 0 0 |
3 0 0 |
1 2 2 |
Total |
0 |
0 |
1 |
4 |
0 |
0 |
3 |
5 |
|
|
|
|
|
|
|
|
|
Number of tissues examined |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
|
|
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies